Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 18/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1752126 | 0.91 | REN (0.43) | RENCYP3A4KCNH2TACR1 | |
| SCHEMBL1751224 | 0.90 | REN (0.45) | RENCYP3A4KCNH2 | |
| SCHEMBL661553 | 0.90 | REN (0.38) | RENCYP3A4KCNH2 | |
| SCHEMBL1518498 | 0.88 | REN (0.43) | RENCYP3A4KCNH2TACR1 | |
| SCHEMBL1751560 | 0.87 | REN (0.40) | RENCYP3A4KCNH2 | |
| SCHEMBL660633 | 0.87 | REN (0.53) | RENCYP3A4KCNH2 | |
| SCHEMBL1750635 | 0.86 | PTGDR2 (0.45) | RENCYP3A4KCNH2 | |
| SCHEMBL1750507 | 0.86 | REN (0.49) | RENCYP3A4KCNH2 | |
| SCHEMBL1750990 | 0.85 | REN (0.39) | RENCYP3A4KCNH2 | |
| SCHEMBL662365 | 0.84 | REN (0.40) | RENCYP3A4KCNH2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | disclosed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | disclosed |
| EP-1981847-A1 | SECONDARY AMINES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007088514-A1 | SECONDARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | REN, ACE, AGTR1 | REN 1/4885CYP3A4 441/4885KCNH2 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.